bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table 5 from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
Authors: Kemp Clinton D. , Rao Mahadev , Xi Sichuan , Inchauste Suzanne , Mani Haresh , Fetsch Patricia , Filie Armando , Zhang Mary , Hong Julie A. , Walker Robert L. , Zhu Yuelin J. , Ripley R. Taylor , Mathur Aarti , Liu Fang , Yang Maocheng , Meltzer Paul A. , Marquez Victor E. , De Rienzo Assunta , Bueno Raphael , Schrump David S.
Published: April 2023

PDF file - 65K, Top 20 Gene Sets Enriched in MES1 and H28 Cells following DZNep Treatment.
Supplementary Table 1 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
Authors: Smith Neil R. , Baker Dawn , Farren Matthew , Pommier Aurelien , Swann Ruth , Wang Xin , Mistry Sunita , McDaid Karen , Kendrew Jane , Womack Chris , Wedge Stephen R. , Barry Simon T.
Published: April 2023

PDF file - 14K, Cancer indications approved for VEGF signalling inhibitors.
Supplementary Table 3 from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
Authors: Kemp Clinton D. , Rao Mahadev , Xi Sichuan , Inchauste Suzanne , Mani Haresh , Fetsch Patricia , Filie Armando , Zhang Mary , Hong Julie A. , Walker Robert L. , Zhu Yuelin J. , Ripley R. Taylor , Mathur Aarti , Liu Fang , Yang Maocheng , Meltzer Paul A. , Marquez Victor E. , De Rienzo Assunta , Bueno Raphael , Schrump David S.
Published: April 2023

PDF file - 57K, SuperArray Analysis of Oncogenes, Tumor Suppressors, and Stem Cell-Related Genes in MPM Lines Following Selective PRC2 Knockdown or 5 �M DZNep.
Supplementary Table 1 from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
Authors: Kemp Clinton D. , Rao Mahadev , Xi Sichuan , Inchauste Suzanne , Mani Haresh , Fetsch Patricia , Filie Armando , Zhang Mary , Hong Julie A. , Walker Robert L. , Zhu Yuelin J. , Ripley R. Taylor , Mathur Aarti , Liu Fang , Yang Maocheng , Meltzer Paul A. , Marquez Victor E. , De Rienzo Assunta , Bueno Raphael , Schrump David S.
Published: April 2023

PDF file - 661K, TaqMan Primers, shRNA, and Antibodies.
Supplementary Materials and Methods from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
Authors: Kemp Clinton D. , Rao Mahadev , Xi Sichuan , Inchauste Suzanne , Mani Haresh , Fetsch Patricia , Filie Armando , Zhang Mary , Hong Julie A. , Walker Robert L. , Zhu Yuelin J. , Ripley R. Taylor , Mathur Aarti , Liu Fang , Yang Maocheng , Meltzer Paul A. , Marquez Victor E. , De Rienzo Assunta , Bueno Raphael , Schrump David S.
Published: April 2023

PDF file - 97K, Supplementary Materials and Methods.
Supplementary Figure 6 from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
Authors: Kemp Clinton D. , Rao Mahadev , Xi Sichuan , Inchauste Suzanne , Mani Haresh , Fetsch Patricia , Filie Armando , Zhang Mary , Hong Julie A. , Walker Robert L. , Zhu Yuelin J. , Ripley R. Taylor , Mathur Aarti , Liu Fang , Yang Maocheng , Meltzer Paul A. , Marquez Victor E. , De Rienzo Assunta , Bueno Raphael , Schrump David S.
Published: April 2023

PDF file - 57K, Effects of DZNep treatment on gene expression in MPM cells: qRT-PCR and correlative immunoblot analysis of p21 and RASSF1A expression in MES1 cells following knock-down of EZH2 or EED, or 5 mM DZNep treatment.
Supplementary Figure 4 from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
Authors: Kemp Clinton D. , Rao Mahadev , Xi Sichuan , Inchauste Suzanne , Mani Haresh , Fetsch Patricia , Filie Armando , Zhang Mary , Hong Julie A. , Walker Robert L. , Zhu Yuelin J. , Ripley R. Taylor , Mathur Aarti , Liu Fang , Yang Maocheng , Meltzer Paul A. , Marquez Victor E. , De Rienzo Assunta , Bueno Raphael , Schrump David S.
Published: April 2023

PDf file - 63K, qRT-PCR and immunoblot analysis of EZH2 and EED levels in MPM lines following transduction with shRNA targeting EZH2, EED, or sham sequences. Effects of knock-down of EZH2 and EED on proliferation of MPM lines.
Supplementary Figure 3 from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
Authors: Kemp Clinton D. , Rao Mahadev , Xi Sichuan , Inchauste Suzanne , Mani Haresh , Fetsch Patricia , Filie Armando , Zhang Mary , Hong Julie A. , Walker Robert L. , Zhu Yuelin J. , Ripley R. Taylor , Mathur Aarti , Liu Fang , Yang Maocheng , Meltzer Paul A. , Marquez Victor E. , De Rienzo Assunta , Bueno Raphael , Schrump David S.
Published: April 2023

PDF file - 66K, Summary of percentages of mesothelioma or normal mesothelia specimens expressing EZH2 in figure 2D.
Supplementary Table 1 from Ontogeny and Sorafenib Metabolism
Authors: Zimmerman Eric I. , Roberts Justin L. , Li Lie , Finkelstein David , Gibson Alice , Chaudhry Amarjit S. , Schuetz Erin G. , Rubnitz Jeffrey E. , Inaba Hiroto , Baker Sharyn D.
Published: April 2023

PDF file, 53K, Patient demographics and steady-state pharmacokinetics of sorafenib and metabolites.
Supplementary Figures 1 - 9 from Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling
Authors: Qian Changgeng , Lai Cheng-Jung , Bao Rudi , Wang Da-Gong , Wang Jing , Xu Guang-Xin , Atoyan Ruzanna , Qu Hui , Yin Ling , Samson Maria , Zifcak Brian , Ma Anna Wai See , DellaRocca Steven , Borek Mylissa , Zhai Hai-Xiao , Cai Xiong , Voi Maurizio
Published: April 2023

PDF file, 348KB, Figure S1. Synergy between PI3K and HDAC pathway inhibition. Figure S2. CUDC-907 increases acetylation of histone H3 in cultured cancer cells. Figure S3. CUDC-907 increases tubulin acetylation in cultured cancer cells. Figure S4. CUDC-907 increases p53 acetylation in cultured cancer cells. Figure S5. CUDC-907 increases p21 levels in cultured cancer cells. Figure S6. CUDC-907 induces the accumulation of activated caspases-3 and -7. Figure S7. CUDC-907 induces the accumulation of annexin V binding sites. Figure S8. CUDC-907 induces a G2/M cell cycle arrest. Figure S9. CUDC-907 is orally bioavailable and shows intratumoral accumulation.
Supplementary Figure Legends from Genomic Heterogeneity of Translocation Renal Cell Carcinoma
Authors: Malouf Gabriel G. , Monzon Federico A. , Couturier Jérôme , Molinié Vincent , Escudier Bernard , Camparo Philippe , Su Xiaoping , Yao Hui , Tamboli Pheroze , Lopez-Terrada Dolores , Picken Maria , Garcia Marileila , Multani Asha S. , Pathak Sen , Wood Christopher G. , Tannir Nizar M.
Published: April 2023

PDF file - 62K
Supplementary Table 5 from Molecular Profiling of Aromatase Inhibitor–Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance
Authors: Dunbier Anita K. , Ghazoui Zara , Anderson Helen , Salter Janine , Nerurkar Ashutosh , Osin Peter , A'hern Roger , Miller William R. , Smith Ian E. , Dowsett Mitch
Published: April 2023

PDF file - 46K, Prediction analysis of correlated genes.
Supplementary Table 3 from Molecular Profiling of Aromatase Inhibitor–Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance
Authors: Dunbier Anita K. , Ghazoui Zara , Anderson Helen , Salter Janine , Nerurkar Ashutosh , Osin Peter , A'hern Roger , Miller William R. , Smith Ian E. , Dowsett Mitch
Published: April 2023

PDF file - 81K, IPA analysis and genes in the inflammatory immune response signature.
Supplementary Figure Legends from Novel Targeting of Phospho-cMET Overcomes Drug Resistance and Induces Antitumor Activity in Multiple Myeloma
Authors: Moschetta Michele , Basile Antonio , Ferrucci Arianna , Frassanito Maria Antonia , Rao Luigia , Ria Roberto , Solimando Antonio Giovanni , Giuliani Nicola , Boccarelli Angelina , Fumarola Fabio , Coluccia Mauro , Rossini Bernardo , Ruggieri Simona , Nico Beatrice , Maiorano Eugenio , Ribatti Domenico , Roccaro Aldo M. , Vacca Angelo
Published: April 2023

PDF file, 16K.
Supplementary Figure Legend from Molecular Profiling of Aromatase Inhibitor–Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance
Authors: Dunbier Anita K. , Ghazoui Zara , Anderson Helen , Salter Janine , Nerurkar Ashutosh , Osin Peter , A'hern Roger , Miller William R. , Smith Ian E. , Dowsett Mitch
Published: April 2023

PDF file - 65K
Supplementary Figure 3 from Molecular Profiling of Aromatase Inhibitor–Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance
Authors: Dunbier Anita K. , Ghazoui Zara , Anderson Helen , Salter Janine , Nerurkar Ashutosh , Osin Peter , A'hern Roger , Miller William R. , Smith Ian E. , Dowsett Mitch
Published: April 2023

PDF file - 87K, Lymphocytic infiltration in tumours.
Supplementary Figure 2 from Molecular Profiling of Aromatase Inhibitor–Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance
Authors: Dunbier Anita K. , Ghazoui Zara , Anderson Helen , Salter Janine , Nerurkar Ashutosh , Osin Peter , A'hern Roger , Miller William R. , Smith Ian E. , Dowsett Mitch
Published: April 2023

PDF file - 826K, Clustering of the tumours based on immunohistochemical parameters.
Supplementary Figure 4 from Novel Targeting of Phospho-cMET Overcomes Drug Resistance and Induces Antitumor Activity in Multiple Myeloma
Authors: Moschetta Michele , Basile Antonio , Ferrucci Arianna , Frassanito Maria Antonia , Rao Luigia , Ria Roberto , Solimando Antonio Giovanni , Giuliani Nicola , Boccarelli Angelina , Fumarola Fabio , Coluccia Mauro , Rossini Bernardo , Ruggieri Simona , Nico Beatrice , Maiorano Eugenio , Ribatti Domenico , Roccaro Aldo M. , Vacca Angelo
Published: April 2023

PDF file, 77K, An anti-cMET neutralizing antibody leads to modulation of phospho(p)-proteins in MM cell lines.
Supplementary Table 2 from Clinical Significance and Prognostic Value of microRNA Expression Signatures in Hepatocellular Carcinoma
Authors: Wei Rongrong , Huang Guo-Liang , Zhang Mei-Yin , Li Bin-Kui , Zhang Hui-Zhong , Shi Ming , Chen Xiao-Qian , Huang Long , Zhou Qing-Ming , Jia Wei-Hua , Zheng X.F. Steven , Yuan Yun-Fei , Wang Hui-Yun
Published: April 2023

PDF file, 148K, Class Prediction with PAM in Test Set and Independent Cohort.
Supplementary Table 1 from Clinical Significance and Prognostic Value of microRNA Expression Signatures in Hepatocellular Carcinoma
Authors: Wei Rongrong , Huang Guo-Liang , Zhang Mei-Yin , Li Bin-Kui , Zhang Hui-Zhong , Shi Ming , Chen Xiao-Qian , Huang Long , Zhou Qing-Ming , Jia Wei-Hua , Zheng X.F. Steven , Yuan Yun-Fei , Wang Hui-Yun
Published: April 2023

PDF file, 97K, Overall survival (OS) and disease-free survival (DFS) in Training set, Test Set and Independent Cohort.
Supplementary Figure Legends from Clinical Significance and Prognostic Value of microRNA Expression Signatures in Hepatocellular Carcinoma
Authors: Wei Rongrong , Huang Guo-Liang , Zhang Mei-Yin , Li Bin-Kui , Zhang Hui-Zhong , Shi Ming , Chen Xiao-Qian , Huang Long , Zhou Qing-Ming , Jia Wei-Hua , Zheng X.F. Steven , Yuan Yun-Fei , Wang Hui-Yun
Published: April 2023

PDF file, 40K.
Supplementary Table 3 from Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents
Authors: Mao Muling , Tian Feng , Mariadason John M. , Tsao Chun C. , Lemos Robert , Dayyani Farshid , Gopal Y.N. Vashisht , Jiang Zhi-Qin , Wistuba Ignacio I. , Tang Xi M. , Bornman William G. , Bollag Gideon , Mills Gordon B. , Powis Garth , Desai Jayesh , Gallick Gary E. , Davies Michael A. , Kopetz Scott
Published: April 2023

PDF file - 48K, RPPA data for the colon and melanoma cell lines. Values are log-base 2, normalized to both total protein loading per sample and the median protein expression. HT29/WiDr, and Colo201/Colo205 are derived from the same patient under different time courses/conditions, and therefore may be provide limited additional data (Semple TU et al., Cancer Res. 1978 May;38(5):1345-55, Chen TR et al Cancer Genet Cytogenet. 1987 Jul;27(1):125-34). Sensitivity analysis demonstrates no change in the conclusions with the inclusion or exclusion of these isogenic cell lines.
Supplementary Figures 1 - 2 from Identification of Circulating MicroRNA Signatures for Breast Cancer Detection
Authors: Chan Maurice , Liaw Chiew Suan , Ji Shen Mo , Tan Hwee Huang , Wong Chow Yin , Thike Aye Aye , Tan Puay Hoon , Ho Gay Hui , Lee Ann Siew-Gek
Published: April 2023

PDF file - 189K, Supplementary Fig. S1: Three components principal component analysis of (a) tissue and (b) serum samples. Breast cancer tumour tissues (a) and serum from breast cancer patients (b) are indicated in red. Adjacent normal tissues (a) and serum from healthy individuals (b) are indicated in blue. Supplementary Fig. S2: Correlation plots from inter-platform comparison studies. (a) same breast cancer tumour sample extracted by mirVana and miRNeasy; (b) same breast cancer tumour sample ran on microarray and RT-PCR panels.
Supplementary Figure 7 from Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents
Authors: Mao Muling , Tian Feng , Mariadason John M. , Tsao Chun C. , Lemos Robert , Dayyani Farshid , Gopal Y.N. Vashisht , Jiang Zhi-Qin , Wistuba Ignacio I. , Tang Xi M. , Bornman William G. , Bollag Gideon , Mills Gordon B. , Powis Garth , Desai Jayesh , Gallick Gary E. , Davies Michael A. , Kopetz Scott
Published: April 2023

PDF file - 46K, HT29 and Colo205 parental and PLX-resistant (RC) cell lines were profiled by Affymetrix U133A for gene expression. Additional candidate genes in the MAPK and AKT pathway are shown below. Each point represents the relative expression of a single probe (relative expression of resistant cell to parental) for each of the specified genes.
Supplementary Figure 6 from Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents
Authors: Mao Muling , Tian Feng , Mariadason John M. , Tsao Chun C. , Lemos Robert , Dayyani Farshid , Gopal Y.N. Vashisht , Jiang Zhi-Qin , Wistuba Ignacio I. , Tang Xi M. , Bornman William G. , Bollag Gideon , Mills Gordon B. , Powis Garth , Desai Jayesh , Gallick Gary E. , Davies Michael A. , Kopetz Scott
Published: April 2023

PDF file - 84K, HT29 and Colo205 parental and PLX-resistant (RC) cell lines subjected to FISH for EGFR. A) Representative fields from each of the 4 cell lines are shown below, with red EGFR probe and green Chr7 centromeric probe. B) FISH scoring confirms HT29RC amplification, compared to centromeric control.
Supplementary Table 1 from MicroRNA-494 Downregulates KIT and Inhibits Gastrointestinal Stromal Tumor Cell Proliferation
Authors: Kim Won Kyu , Park Misun , Kim Young-Kook , Tae You Kwon , Yang Han-Kwang , Lee Jae Myun , Kim Hoguen
Published: April 2023

PDF file - 47K
Supplementary Figure Legends 1-8 from MicroRNA-494 Downregulates KIT and Inhibits Gastrointestinal Stromal Tumor Cell Proliferation
Authors: Kim Won Kyu , Park Misun , Kim Young-Kook , Tae You Kwon , Yang Han-Kwang , Lee Jae Myun , Kim Hoguen
Published: April 2023

PDF file - 146K
Supplementary Figure 3 from Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents
Authors: Mao Muling , Tian Feng , Mariadason John M. , Tsao Chun C. , Lemos Robert , Dayyani Farshid , Gopal Y.N. Vashisht , Jiang Zhi-Qin , Wistuba Ignacio I. , Tang Xi M. , Bornman William G. , Bollag Gideon , Mills Gordon B. , Powis Garth , Desai Jayesh , Gallick Gary E. , Davies Michael A. , Kopetz Scott
Published: April 2023

PDF file - 338K, Cells were incubated for 24h (HT29, Colon205) or 48 h (RKO) with PLX4720 (1 M for all cell lines), LY294002 (15 M for all cell lines) or their combination. Cells were then harvested and stained with propidium iodide. DNA concentrations were measured by FACS. The data represent mean values from three independent experiments. (# represents P < 0.01)
Supplementary Figure 1 from Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents
Authors: Mao Muling , Tian Feng , Mariadason John M. , Tsao Chun C. , Lemos Robert , Dayyani Farshid , Gopal Y.N. Vashisht , Jiang Zhi-Qin , Wistuba Ignacio I. , Tang Xi M. , Bornman William G. , Bollag Gideon , Mills Gordon B. , Powis Garth , Desai Jayesh , Gallick Gary E. , Davies Michael A. , Kopetz Scott
Published: April 2023

PDF file - 36K, Correlation of EGFR and PTEN expression by RPPA and sensitivity to PLX4720. There is no statistically significant correlation between the EGFR expression level and sensitivity to PLX4720 (P=0.10, Spearman rank), although this is influenced by outliers at both extremes of sensitivity. PTEN expression is likewise not statistically significantly correlated with sensitivity (P=0.4). Together, either loss of PTEN or higher EGFR expression is associated with resistance to PLX4720 (P=0.048, Fisher's exact).
Supplementary Figure 3 from MicroRNA-494 Downregulates KIT and Inhibits Gastrointestinal Stromal Tumor Cell Proliferation
Authors: Kim Won Kyu , Park Misun , Kim Young-Kook , Tae You Kwon , Yang Han-Kwang , Lee Jae Myun , Kim Hoguen
Published: April 2023

PDF file - 2.0MB
Supplementary Figure 1 from MicroRNA-494 Downregulates KIT and Inhibits Gastrointestinal Stromal Tumor Cell Proliferation
Authors: Kim Won Kyu , Park Misun , Kim Young-Kook , Tae You Kwon , Yang Han-Kwang , Lee Jae Myun , Kim Hoguen
Published: April 2023

PDF file - 2.6MB
Supplementary Figure 2 from A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer
Authors: Berlin Jordan , Bendell Johanna C. , Hart Lowell L. , Firdaus Irfan , Gore Ira , Hermann Robert C. , Mulcahy Mary F. , Zalupski Mark M. , Mackey Howard M. , Yauch Robert L. , Graham Richard A. , Bray Gordon L. , Low Jennifer A.
Published: April 2023

PDF file - 25K, A comparison of steady-state 5-FU concentrations with and without vismodegib co-treatment
Supplementary Figure Legend from microRNA Expression Profiles Identify Subtypes of Mantle Cell Lymphoma with Different Clinicobiological Characteristics
Authors: Navarro Alba , Clot Guillem , Prieto Miriam , Royo Cristina , Vegliante Maria Carmela , Amador Virginia , Hartmann Elena , Salaverria Itziar , Beà Sílvia , Martín-Subero Jose Ignacio , Rosenwald Andreas , Ott German , Wiestner Adrian , Wilson Wyndham H. , Campo Elías , Hernández Luis
Published: April 2023

PDF file - 73K
Supplementary Figure Legend from Prolonged Postovulatory Proinflammatory Signaling in the Fallopian Tube Epithelium May Be Mediated through a BRCA1/DAB2 Axis
Authors: Tone Alicia A. , Virtanen Carl , Shaw Patricia , Brown Theodore J.
Published: April 2023

PDF file, 98K.
Supplementary Figure Legend from Individual Patient-Specific Immunity against High-Grade Glioma after Vaccination with Autologous Tumor Derived Peptides Bound to the 96 KD Chaperone Protein
Authors: Crane Courtney A. , Han Seunggu J. , Ahn Brian , Oehlke Jessica , Kivett Valerie , Fedoroff Anne , Butowski Nicholas , Chang Susan M. , Clarke Jennifer , Berger Mitchel S. , McDermott Michael W. , Prados Michael D. , Parsa Andrew T.
Published: April 2023

PDF file, 69K.
CCR Translation for This Article from EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma
Authors: He Mai , Capelletti Marzia , Nafa Khedoudja , Yun Cai-Hong , Arcila Maria E. , Miller Vincent A. , Ginsberg Michelle S. , Zhao Binsheng , Kris Mark G. , Eck Michael J. , Jänne Pasi A. , Ladanyi Marc , Oxnard Geoffrey R.
Published: April 2023

CCR Translation for This Article from EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma
Supplementary Figure 1 from In Vivo Phosphoantigen Levels in Bisphosphonate-Treated Human Breast Tumors Trigger Vγ9Vδ2 T-cell Antitumor Cytotoxicity through ICAM-1 Engagement
Authors: Benzaïd Ismahène , Mönkkönen Hannu , Bonnelye Edith , Mönkkönen Jukka , Clézardin Philippe
Published: April 2023

PDF file - 195K, RIS induced Vγ9Vδ2 T-cell expansion in vitro and IPP/ApppI production in human PBMCs
Supplementary Methods from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia
Authors: Lionetti Marta , Musto Pellegrino , Di Martino Maria Teresa , Fabris Sonia , Agnelli Luca , Todoerti Katia , Tuana Giacomo , Mosca Laura , Gallo Cantafio Maria E. , Grieco Vitina , Bianchino Gabriella , D'Auria Fiorella , Statuto Teodora , Mazzoccoli Carmela , De Luca Luciana , Petrucci Maria Teresa , Offidani Massimo , Di Raimondo Francesco , Falcone Antonietta , Caravita Tommaso , Omede' Paola , Morabito Fortunato , Tassone Pierfrancesco , Boccadoro Mario , Palumbo Antonio , Neri Antonino
Published: April 2023

PDF file - 39K
Supplementary Figure 2 from Circulating miRNAs as Surrogate Markers for Circulating Tumor Cells and Prognostic Markers in Metastatic Breast Cancer
Authors: Madhavan Dharanija , Zucknick Manuela , Wallwiener Markus , Cuk Katarina , Modugno Caroline , Scharpff Martina , Schott Sarah , Heil Jörg , Turchinovich Andrey , Yang Rongxi , Benner Axel , Riethdorf Sabine , Trumpp Andreas , Sohn Christof , Pantel Klaus , Schneeweiss Andreas , Burwinkel Barbara
Published: April 2023

PDF file, 90K, Partial correlations between miRNAs.
Supplementary Figure 2 from A Functional Variant at 19q13.3, rs967591G>A, Is Associated with Shorter Survival of Early-Stage Lung Cancer
Authors: Jeon Hyo-Sung , Jin Guang , Kang Hyo-Gyoung , Choi Yi Young , Lee Won Kee , Choi Jin Eun , Bae Eun Young , Yoo Seung Soo , Lee Shin Yup , Lee Eung Bae , Kim Young Tae , Lee Jaehee , Cha Seung-Ick , Kim Chang Ho , Jheon Sanghoon , Kim In San , Park Jae Yong
Published: April 2023

PDF file - 29K, Luciferase activity according to rs967591G>A with E2 or 4-OHT treatment in H1299 cells.
Supplementary Table 5B from AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity
Authors: Yap Timothy A. , Walton Mike I. , Grimshaw Kyla M. , te Poele Robert H. , Eve Paul D. , Valenti Melanie R. , de Haven Brandon Alexis K. , Martins Vanessa , Zetterlund Anna , Heaton Simon P. , Heinzmann Kathrin , Jones Paul S. , Feltell Ruth E. , Reule Matthias , Woodhead Steven J. , Davies Thomas G. , Lyons John F. , Raynaud Florence I. , Eccles Suzanne A. , Workman Paul , Thompson Neil T. , Garrett Michelle D.
Published: April 2023

XLS file - 703K, Gene expression data for CCT128930: Genes that showed at least a 1.5 Fold Change in at least one treated sample compared to vehicle control and were differentially expressed between the treatment groups (Welch ANOVA FDR5%)
CCR Translation for This Article from BCL2 Predicts Survival in Germinal Center B-cell–like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab
Authors: Iqbal Javeed , Meyer Paul N. , Smith Lynette M. , Johnson Nathalie A. , Vose Julie M. , Greiner Timothy C. , Connors Joseph M. , Staudt Louis M. , Rimsza Lisa , Jaffe Elaine , Rosenwald Andreas , Ott German , Delabie Jan , Campo Elias , Braziel Rita M. , Cook James R. , Tubbs Raymond R. , Gascoyne Randy D. , Armitage James O. , Weisenburger Dennis D. , Chan Wing C.
Published: April 2023

CCR Translation for This Article from BCL2 Predicts Survival in Germinal Center B-cell–like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab
Supplementary Methods, Figure Legends 1-7 from AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity
Authors: Yap Timothy A. , Walton Mike I. , Grimshaw Kyla M. , te Poele Robert H. , Eve Paul D. , Valenti Melanie R. , de Haven Brandon Alexis K. , Martins Vanessa , Zetterlund Anna , Heaton Simon P. , Heinzmann Kathrin , Jones Paul S. , Feltell Ruth E. , Reule Matthias , Woodhead Steven J. , Davies Thomas G. , Lyons John F. , Raynaud Florence I. , Eccles Suzanne A. , Workman Paul , Thompson Neil T. , Garrett Michelle D.
Published: April 2023

PDF file - 81K, Supplementary data comprising the materials and methods for (i) crystallography (ii) gene expression studies (iii) siRNA studies and Supplementary Figure legends 1-7
Supplementary Figure 3 from Development and Preclinical Characterization of a Humanized Antibody Targeting CXCL12
Authors: Zhong Cuiling , Wang Jianyong , Li Bing , Xiang Hong , Ultsch Mark , Coons Mary , Wong Terence , Chiang Nancy Y. , Clark Suzy , Clark Robyn , Quintana Leah , Gribling Peter , Suto Eric , Barck Kai , Corpuz Racquel , Yao Jenny , Takkar Rashi , Lee Wyne P. , Damico-Beyer Lisa A. , Carano Richard D. , Adams Camellia , Kelley Robert F. , Wang Weiru , Ferrara Napoleone
Published: April 2023

PDF file, 239K, Intervention studies in the laser-induced choroidal neovascularization (CNV) model.
Supplementary Figure 2 from Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models
Authors: Diamond Jennifer R. , Eckhardt S. Gail , Tan Aik Choon , Newton Timothy P. , Selby Heather M. , Brunkow Kelsey L. , Kachaeva Maria I. , Varella-Garcia Marileila , Pitts Todd M. , Bray Mark R. , Fletcher Graham C. , Tentler John J.
Published: April 2023

PDF file - 173K, Phospho-receptor tyrosine kinase (phospho-RTK) array analysis
Data Supplement from Evidence for Molecular Differences in Prostate Cancer between African American and Caucasian Men
Authors: Khani Francesca , Mosquera Juan Miguel , Park Kyung , Blattner Mirjam , O'Reilly Catherine , MacDonald Theresa Y. , Chen Zhengming , Srivastava Abhishek , Tewari Ashutosh K. , Barbieri Christopher E. , Rubin Mark A. , Robinson Brian D.
Published: April 2023

Supplemental Table S1: Association of Clinical and Pathologic Characteristics with Molecular Abnormalities (CaM Cohort Only). Supplemental Table S2: Association of Clinical and Pathologic Characteristics with Molecular Abnormalities (AAM Cohort Only).
Data Supplement from Influence of Biospecimen Variables on Proteomic Biomarkers in Breast Cancer
Authors: Meric-Bernstam Funda , Akcakanat Argun , Chen Huiqin , Sahin Aysegul , Tarco Emily , Carkaci Selin , Adrada Beatriz E. , Singh Gopal , Do Kim-Anh , Garces Zerzhinski M. , Mittendorf Elizabeth , Babiera Gildy , Bedrosian Isabelle , Hwang Rosa , Krishnamurthy Savitri , Symmans William F. , Gonzalez-Angulo Ana Maria , Mills Gordon B.
Published: April 2023

Legends for Supplementary Tables 1-11
Supplementary Figure 5 from Serum Glutamate Levels Correlate with Gleason Score and Glutamate Blockade Decreases Proliferation, Migration, and Invasion and Induces Apoptosis in Prostate Cancer Cells
Authors: Koochekpour Shahriar , Majumdar Sunipa , Azabdaftari Gissou , Attwood Kristopher , Scioneaux Ray , Subramani Dhatchayini , Manhardt Charles , Lorusso Giovanni D. , Willard Stacey S. , Thompson Hillary , Shourideh Mojgan , Rezaei Katayoon , Sartor Oliver , Mohler James L. , Vessella Robert L.
Published: April 2023

PDF file - 188K, Scratch-wound migration assays
Supplementary Figure 1 from Serum Glutamate Levels Correlate with Gleason Score and Glutamate Blockade Decreases Proliferation, Migration, and Invasion and Induces Apoptosis in Prostate Cancer Cells
Authors: Koochekpour Shahriar , Majumdar Sunipa , Azabdaftari Gissou , Attwood Kristopher , Scioneaux Ray , Subramani Dhatchayini , Manhardt Charles , Lorusso Giovanni D. , Willard Stacey S. , Thompson Hillary , Shourideh Mojgan , Rezaei Katayoon , Sartor Oliver , Mohler James L. , Vessella Robert L.
Published: April 2023

PDF file - 156K, Comparison of serum glutamate levels in African Americans and Caucasian Americans with metastatic-castrate resistant prostate cancer
Supplementary Table 5 from Predicting Drug Responsiveness in Human Cancers Using Genetically Engineered Mice
Authors: Usary Jerry , Zhao Wei , Darr David , Roberts Patrick J. , Liu Mei , Balletta Lorraine , Karginova Olga , Jordan Jamie , Combest Austin , Bridges Arlene , Prat Aleix , Cheang Maggie C. U. , Herschkowitz Jason I. , Rosen Jeffrey M. , Zamboni William , Sharpless Norman E. , Perou Charles M.
Published: April 2023

PDF file - 42K, Summary of drugs used in this study.
Supplementary Methods from The Critical Role of Dysregulated FOXM1–PLAUR Signaling in Human Colon Cancer Progression and Metastasis
Authors: Li Dawei , Wei Ping , Peng Zhihai , Huang Chen , Tang Huamei , Jia Zhiliang , Cui Jiujie , Le Xiangdong , Huang Suyun , Xie Keping
Published: April 2023

PDF file - 107K
Supplementary Data from Relapsed Classic E-Cadherin (CDH1)–Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER2 (ERBB2) Gene Mutations
Authors: Ross Jeffrey S. , Wang Kai , Sheehan Christine E. , Boguniewicz Ann B. , Otto Geoff , Downing Sean R. , Sun James , He Jie , Curran John A. , Ali Siraj , Yelensky Roman , Lipson Doron , Palmer Gary , Miller Vincent A. , Stephens Philip J.
Published: April 2023

Supplementary Data from Relapsed Classic E-Cadherin (CDH1)–Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER2 (ERBB2) Gene Mutations
Supplementary Table 1 from Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study
Authors: Ang Joo Ern , Gourley Charlie , Powell C. Bethan , High Hilda , Shapira-Frommer Ronnie , Castonguay Vincent , De Greve Jacques , Atkinson Tina , Yap Timothy A. , Sandhu Shahneen , Banerjee Susana , Chen Lee-May , Friedlander Michael L. , Kaufman Bella , Oza Amit M. , Matulonis Ursula , Barber Louise J. , Kozarewa Iwanka , Fenwick Kerry , Assiotis Ioannis , Campbell James , Chen Lina , de Bono Johann S. , Gore Martin E. , Lord Christopher J. , Ashworth Alan , Kaye Stan B.
Published: April 2023

Supplementary Table 1 - PDF file 57K, Supplementary Table 1. Details of platinum sensitivity and best response to olaparib and post-PARPi chemotherapy of the six patients whose tumor samples were analyzed by massively parallel sequencing. (NE: not evaluable)
Supplementary Figure 5 from Novel Tumor Subgroups of Urothelial Carcinoma of the Bladder Defined by Integrated Genomic Analysis
Authors: Hurst Carolyn D. , Platt Fiona M. , Taylor Claire F. , Knowles Margaret A.
Published: April 2023

PDF file, 3635K, Unsupervised hierarchical cluster analysis of aCGH data from all tumor samples and genome-wide frequency plots of copy number alterations in individual ≥T2 clusters.
Supplementary Figure 2 from IL-10 Promotes Tumor Aggressiveness via Upregulation of CIP2A Transcription in Lung Adenocarcinoma
Authors: Sung Wen-Wei , Wang Yao-Chen , Lin Po-Lin , Cheng Ya-Wen , Chen Chih-Yi , Wu Tzu-Chin , Lee Huei
Published: April 2023

Supplementary Figure 2 - PDF file 65K, Kaplan-Meier analysis was used to assess the influence of IL-10 and CIP2A on overall survival in (A) all study population, (B) patients with HPV 16/18 E6 positive tumor, and (C) patients with HPV 16/18 E6 negative tumor
Supplementary Methods, Figures 1 - 3, Tables 1 - 4 from Deregulation of a Hox Protein Regulatory Network Spanning Prostate Cancer Initiation and Progression
Authors: Chen James L. , Li Jianrong , Kiriluk Kyle J. , Rosen Alex M. , Paner Gladell P. , Antic Tatjana , Lussier Yves A. , Vander Griend Donald J.
Published: April 2023

PDF file, 315KB, Supplemental Figure 1: Validation of differential Meis1 and Meis2 expression between Prostate and Seminal Vesicle Epithelial Cells. Supplemental Figure 2: Gene expression profiles from 181 prostatectomy specimens of patients (Taylor dataset) using the PAM (Prediction Analysis for Microarrays) algorithm to stratify patients into two groups based on changes in expression of Meis1, Meis2, Pbx1, HoxA9, HoxB7. Supplemental Figure 3: Meis biomodule network analysis. Supplemental Methods: qPCR Analyses of Meis1 and Meis2. Supplemental Table 1: Historical datasets used in the analyses. Supplemental Table 2: Prostate epithelial cell (PrEC) versus seminal epithelial cell (SVEC) culture differentially expressed genes. Supplemental Table 3: Functional Annotation of the Prostate versus Seminal Vesicle Epithelium Signature. Supplementary Table 4: Univariate and Multivariate Cox Regression.
Supplementary Figure 3 from Metronomic Activity of CD44-Targeted Hyaluronic Acid-Paclitaxel in Ovarian Carcinoma
Authors: Lee Sun Joo , Ghosh Sukhen C. , Han Hee Dong , Stone Rebecca L. , Bottsford-Miller Justin , Shen De Yue , Auzenne Edmond J. , Lopez-Araujo Alejandro , Lu Chunhua , Nishimura Masato , Pecot Chad V. , Zand Behrouz , Thanapprapasr Duangmani , Jennings Nicholas B , Kang Yu , Huang Jie , Hu Wei , Klostergaard Jim , Sood Anil K.
Published: April 2023

PDF file, 366KB, Effects of MET and MTD HA-TXL treatment in the HeyA8-MDR model on biological endpoints.
Supplementary Figure S7 from Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma
Authors: Nadal Ernest , Chen Guoan , Gallegos Marc , Lin Lin , Ferrer-Torres Daysha , Truini Anna , Wang Zhuwen , Lin Jules , Reddy Rishindra M. , Llatjos Roger , Escobar Ignacio , Moya Juan , Chang Andrew C. , Cardenal Felipe , Capellà Gabriel , Beer David G.
Published: April 2023

PDF file 103K, Cisplatin chemosensitivity in SK-LU-1 miR-34b/c transfected cells
Supplementary Methods from Impact of Expression of Human Epidermal Growth Factor Receptors EGFR and ERBB2 on Survival in Stage II/III Gastric Cancer
Authors: Terashima Masanori , Kitada Koji , Ochiai Atsushi , Ichikawa Wataru , Kurahashi Issei , Sakuramoto Shinichi , Katai Hitoshi , Sano Takeshi , Imamura Hiroshi , Sasako Mitsuru
Published: April 2023

PDF file - 127K
Supplementary Table 2 from Brachyury, a Driver of the Epithelial–Mesenchymal Transition, Is Overexpressed in Human Lung Tumors: An Opportunity for Novel Interventions against Lung Cancer
Authors: Roselli Mario , Fernando Romaine I. , Guadagni Fiorella , Spila Antonella , Alessandroni Jhessica , Palmirotta Raffaele , Costarelli Leopoldo , Litzinger Mary , Hamilton Duane , Huang Bruce , Tucker Joanne , Tsang Kwong-Yok , Schlom Jeffrey , Palena Claudia
Published: April 2023

PDF file, 55KB, Number and percentage of tissues from adult non-cancer subjects that were positive for Brachyury expression by immunohistochemistry.
Supplementary Figure Legends 1-4 from Costimulatory Protein 4IgB7H3 Drives the Malignant Phenotype of Glioblastoma by Mediating Immune Escape and Invasiveness
Authors: Lemke Dieter , Pfenning Philipp-Niclas , Sahm Felix , Klein Ann-Catherine , Kempf Tore , Warnken Uwe , Schnölzer Martina , Tudoran Ruxandra , Weller Michael , Platten Michael , Wick Wolfgang
Published: April 2023

PDF file - 64K
Supplementary Figure 4 from Costimulatory Protein 4IgB7H3 Drives the Malignant Phenotype of Glioblastoma by Mediating Immune Escape and Invasiveness
Authors: Lemke Dieter , Pfenning Philipp-Niclas , Sahm Felix , Klein Ann-Catherine , Kempf Tore , Warnken Uwe , Schnölzer Martina , Tudoran Ruxandra , Weller Michael , Platten Michael , Wick Wolfgang
Published: April 2023

PDF file - 698K
Supplementary Figure 2 from Costimulatory Protein 4IgB7H3 Drives the Malignant Phenotype of Glioblastoma by Mediating Immune Escape and Invasiveness
Authors: Lemke Dieter , Pfenning Philipp-Niclas , Sahm Felix , Klein Ann-Catherine , Kempf Tore , Warnken Uwe , Schnölzer Martina , Tudoran Ruxandra , Weller Michael , Platten Michael , Wick Wolfgang
Published: April 2023

PDF file - 2.0MB
Supplementary Figure 1 from Costimulatory Protein 4IgB7H3 Drives the Malignant Phenotype of Glioblastoma by Mediating Immune Escape and Invasiveness
Authors: Lemke Dieter , Pfenning Philipp-Niclas , Sahm Felix , Klein Ann-Catherine , Kempf Tore , Warnken Uwe , Schnölzer Martina , Tudoran Ruxandra , Weller Michael , Platten Michael , Wick Wolfgang
Published: April 2023

PDF file - 4.7MB
Supplementary Figure 3 from HAb18G/CD147 Promotes pSTAT3-Mediated Pancreatic Cancer Development via CD44s
Authors: Li Ling , Tang Wenhua , Wu Xiaoqing , Karnak David , Meng Xiaojie , Thompson Rachel , Hao Xinbao , Li Yongmin , Qiao Xiaotan T. , Lin Jiayuh , Fuchs James , Simeone Diane M. , Chen Zhi-Nan , Lawrence Theodore S. , Xu Liang
Published: April 2023

PDF file - 668K, HAb18G/CD147 knock-down efficiency and function validation (related to Figure 1).
Supplementary Tables 1-4, Figure 1 from Search for a Gene Expression Signature of Breast Cancer Local Recurrence in Young Women
Authors: Servant Nicolas , Bollet Marc A. , Halfwerk Hans , Bleakley Kevin , Kreike Bas , Jacob Laurent , Sie Daoud , Kerkhoven Ron M. , Hupé Philippe , Hadhri Rim , Fourquet Alain , Bartelink Harry , Barillot Emmanuel , Sigal-Zafrani Brigitte , van de Vijver Marc J.
Published: April 2023

PDF file - 203K
Supplementary Figure Legend from Temozolomide-Mediated DNA Methylation in Human Myeloid Precursor Cells: Differential Involvement of Intrinsic and Extrinsic Apoptotic Pathways
Authors: Wang Haiyan , Cai Shanbao , Ernstberger Aaron , Bailey Barbara J. , Wang Michael Z. , Cai Wenjing , Goebel W. Scott , Czader Magdalena B. , Crean Colin , Suvannasankha Attaya , Shokolenkoc Inna , Wilson Glenn L. , Baluyut Arthur R. , Mayo Lindsey D. , Pollok Karen E.
Published: April 2023

PDF file - 23K
Supplementary Table 2 from Regulatory Polymorphisms in β-Tubulin IIa Are Associated with Paclitaxel-Induced Peripheral Neuropathy
Authors: Leandro-García Luis J. , Leskelä Susanna , Jara Carlos , Gréen Henrik , Åvall-Lundqvist Elisabeth , Wheeler Heather E. , Dolan M. Eileen , Inglada-Perez Lucia , Maliszewska Agnieszka , de Cubas Aguirre A. , Comino-Méndez Iñaki , Mancikova Veronika , Cascón Alberto , Robledo Mercedes , Rodríguez-Antona Cristina
Published: April 2023

PDF file, 101KB, TUBB2A promoter variants in individuals high and low β-tubulin IIa mRNA expression.
Supplementary Figure Legend from Regulatory Polymorphisms in β-Tubulin IIa Are Associated with Paclitaxel-Induced Peripheral Neuropathy
Authors: Leandro-García Luis J. , Leskelä Susanna , Jara Carlos , Gréen Henrik , Åvall-Lundqvist Elisabeth , Wheeler Heather E. , Dolan M. Eileen , Inglada-Perez Lucia , Maliszewska Agnieszka , de Cubas Aguirre A. , Comino-Méndez Iñaki , Mancikova Veronika , Cascón Alberto , Robledo Mercedes , Rodríguez-Antona Cristina
Published: April 2023

PDF file, 95KB.
Supplementary Figure 1 from Regulatory Polymorphisms in β-Tubulin IIa Are Associated with Paclitaxel-Induced Peripheral Neuropathy
Authors: Leandro-García Luis J. , Leskelä Susanna , Jara Carlos , Gréen Henrik , Åvall-Lundqvist Elisabeth , Wheeler Heather E. , Dolan M. Eileen , Inglada-Perez Lucia , Maliszewska Agnieszka , de Cubas Aguirre A. , Comino-Méndez Iñaki , Mancikova Veronika , Cascón Alberto , Robledo Mercedes , Rodríguez-Antona Cristina
Published: April 2023

PDF file, 41KB, β-tubulin II protein expression in peripheral blood leukocytes.
Supplementary Figure 1, Tables 1-3 from Common PIK3CA Mutants and a Novel 3′ UTR Mutation Are Associated with Increased Sensitivity to Saracatinib
Authors: Arcaroli John J. , Quackenbush Kevin S. , Powell Rebecca W. , Pitts Todd M. , Spreafico Anna , Varella-Garcia Marileila , Bemis Lynne , Tan Aik Choon , Reinemann Jaclyn M. , Touban Basel M. , Dasari Arvind , Eckhardt S. Gail , Messersmith Wells A.
Published: April 2023

PDF file - 295K, The effects of saracatinib on proliferation of CRC cell lines. Twenty-three CRC cell lines were treated with saracatinib (0.0625 um uM) and assayed by SRB 72 hours after exposure to drug. Cell lines (H508, LS180 and LS174T) with an IC50 less than 1 uM were considered sensitive to saracatinib. Cell lines are listed in order from the most resistant to the most sensitive; (R) = resistant, (S) = sensitive. PIK3CA (wt) and (mut) are shown for each cell line. Sup. Table 1: Saracatinib effects, PIK3CA and KRAS mutational status in CRC cell lines. Sup. Table 2: Patient characteristics of CRC explants and distribution of PIK3CA mutations; Sup. Table 3: Src gene copy (FISH) in CRC cell lines and explants. A Src copy number of �3 was considered a gain and < 3 was considered no gain. A significant association (p = 0.0469) was identified between increase in Src gene copy number and resistance to saracatinib.
Supplementary Table 1 from Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies
Authors: Besser Michal J. , Shapira-Frommer Ronnie , Itzhaki Orit , Treves Avraham J. , Zippel Douglas B. , Levy Daphna , Kubi Adva , Shoshani Noa , Zikich Dragoslav , Ohayon Yaara , Ohayon Daniel , Shalmon Bruria , Markel Gal , Yerushalmi Ronit , Apter Sara , Ben-Nun Alon , Ben-Ami Eytan , Shimoni Avichai , Nagler Arnon , Schachter Jacob
Published: April 2023

PDF file - 43K, the objective responses of individual patients to various types of immunotherapies.
Supplementary Figure Legend from Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer
Authors: Tanizaki Junko , Okamoto Isamu , Okabe Takafumi , Sakai Kazuko , Tanaka Kaoru , Hayashi Hidetoshi , Kaneda Hiroyasu , Takezawa Ken , Kuwata Kiyoko , Yamaguchi Haruka , Hatashita Erina , Nishio Kazuto , Nakagawa Kazuhiko
Published: April 2023

PDF file, 65K.
Supplementary Figure 2 from EGFR Protein Expression in Non–Small Cell Lung Cancer Predicts Response to an EGFR Tyrosine Kinase Inhibitor—A Novel Antibody for Immunohistochemistry or AQUA Technology
Authors: Mascaux Celine , Wynes Murry W. , Kato Yasufumi , Tran Cindy , Asuncion Bernadette Reyna , Zhao Jason M. , Gustavson Mark , Ranger-Moore Jim , Gaire Fabien , Matsubayashi Jun , Nagao Toshitaka , Yoshida Koichi , Ohira Tatuso , Ikeda Norihiko , Hirsch Fred R.
Published: April 2023

PDF file - 136KB
Supplementary Figure 7 from Identification of Unique MEK-Dependent Genes in GNAQ Mutant Uveal Melanoma Involved in Cell Growth, Tumor Cell Invasion, and MEK Resistance
Authors: Ambrosini Grazia , Pratilas Christine A. , Qin Li-Xuan , Tadi Madhavi , Surriga Oliver , Carvajal Richard D. , Schwartz Gary K.
Published: April 2023

PDF file, 278KB, Downregulation of c-Jun by siRNA renders GNAQ mutant cells more sensitive to selumetinib.
Supplementary Figure 4 from A Personalized Preclinical Model to Evaluate the Metastatic Potential of Patient-Derived Colon Cancer Initiating Cells
Authors: Puig Isabel , Chicote Irene , Tenbaum Stephan P. , Arqués Oriol , Herance José Raúl , Gispert Juan D. , Jimenez José , Landolfi Stefania , Caci Karina , Allende Helena , Mendizabal Leire , Moreno Debora , Charco Ramón , Espín Eloy , Prat Aleix , Elez Maria Elena , Argilés Guillem , Vivancos Ana , Tabernero Josep , Rojas Santiago , Palmer Héctor G.
Published: April 2023

PDF file - 115K, 18-FDG is the best radiotracer for tumor growth evaluation.
Supplementary Table 1 from Genomic Estimates of Aneuploid Content in Glioblastoma Multiforme and Improved Classification
Authors: Li Bo , Senbabaoglu Yasin , Peng Weiping , Yang Min-Lee , Xu Jishu , Li Jun Z.
Published: April 2023

XLS file, 535K, Genomic features and QC measures for GBM1 and GBM2 (n=284).
Supplementary Materials and Methods, Figure Legends, Tables 1 - 2 from Semi-Mechanistic Pharmacokinetic/Pharmacodynamic Modeling of the Antitumor Activity of LY2835219, a New Cyclin-Dependent Kinase 4/6 Inhibitor, in Mice Bearing Human Tumor Xenografts
Authors: Tate Sonya C. , Cai Shufen , Ajamie Rose T. , Burke Teresa , Beckmann Richard P. , Chan Edward M. , De Dios Alfonso , Wishart Graham N. , Gelbert Lawrence M. , Cronier Damien M.
Published: April 2023

PDF file - 122KB, Supplementary Table 1. Summary of available PK and biomarker data. Supplementary Table 2. Definitions of PK, biomarker and tumor model parameters.
Supplementary Material 3 from The Antibody-Based Delivery of Interleukin-12 to the Tumor Neovasculature Eradicates Murine Models of Cancer in Combination with Paclitaxel
Authors: Pasche Nadine , Wulhfard Sarah , Pretto Francesca , Carugati Elisa , Neri Dario
Published: April 2023

PDF file, 4693KB, Supplementary Material 3. Stability of mIL12-F8-F8 and mIL12-KSF-KSF SDS-PAGE analysis of purified mIL12-F8-F8 and mIL12-KSF-KSF stored in PBS at 37°C for 0, 24, 48, 72 or 96 hours.
Supplementary Figure 6 from Epigenetic Alteration of PRKCDBP in Colorectal Cancers and Its Implication in Tumor Cell Resistance to TNFα-Induced Apoptosis
Authors: Lee Jin-Hee , Kang Min-Ju , Han Hye-Yeon , Lee Min-Goo , Jeong Seong-In , Ryu Byung-Kyu , Ha Tae-Kyu , Her Nam-Goo , Han Jikhyon , Park Sun Jin , Lee Kil Yeon , Kim Hyo-Jong , Chi Sung-Gil
Published: April 2023

PDF file - 98K
Supplementary Figure 4 from Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone
Authors: Ryan Charles J. , Rosenthal Mark , Ng Siobhan , Alumkal Joshi , Picus Joel , Gravis Gwenaëlle , Fizazi Karim , Forget Frédéric , Machiels Jean-Pascal , Srinivas Sandy , Zhu Min , Tang Rui , Oliner Kelly S. , Jiang Yizhou , Loh Elwyn , Dubey Sarita , Gerritsen Winald R.
Published: April 2023

PDF file - 31K, Waterfall plot of the maximum change of PSA levels from baseline in patients who received rilotumumab (A) or placebo (B) in the intention-to-treat analysis set. A PSA response was defined as ≥50% decline in two consecutive PSA levels ≥3 weeks apart. Six patients in the rilotumumab group were omitted because post-baseline data were not available.
Supplementary Figure 3 from Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone
Authors: Ryan Charles J. , Rosenthal Mark , Ng Siobhan , Alumkal Joshi , Picus Joel , Gravis Gwenaëlle , Fizazi Karim , Forget Frédéric , Machiels Jean-Pascal , Srinivas Sandy , Zhu Min , Tang Rui , Oliner Kelly S. , Jiang Yizhou , Loh Elwyn , Dubey Sarita , Gerritsen Winald R.
Published: April 2023

PDF file - 1076K, Kaplan-Meier plot of PFS by tumor MET subgroups in the combined rilotumumab and control arms (A) and forest plot of the biomarker effect of high versus low tumor MET expression on PFS within the combined rilotumumab and control arms (B). MP, mitoxantrone and prednisone; NA, not applicable.
Supplementary Figure 2 from Epigenetic Alteration of PRKCDBP in Colorectal Cancers and Its Implication in Tumor Cell Resistance to TNFα-Induced Apoptosis
Authors: Lee Jin-Hee , Kang Min-Ju , Han Hye-Yeon , Lee Min-Goo , Jeong Seong-In , Ryu Byung-Kyu , Ha Tae-Kyu , Her Nam-Goo , Han Jikhyon , Park Sun Jin , Lee Kil Yeon , Kim Hyo-Jong , Chi Sung-Gil
Published: April 2023

PDF file - 112K
Supplementary Figures 1 - 3, Tables 1 - 3 from Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition
Authors: Troiani Teresa , Napolitano Stefania , Vitagliano Donata , Morgillo Floriana , Capasso Anna , Sforza Vincenzo , Nappi Anna , Ciardiello Davide , Ciardiello Fortunato , Martinelli Erika
Published: April 2023

PDF file - 1325KB, Caption Supplementary Figure 1 A and 1B. The combined treatment of cetuximab and the selective MEK1/2 inhibitor BAY 86-9766 induce a synergistic growth inhibitory effects in CRC cell lines with primary and acquired resistance to cetuximab and an antagonistic effects in cetuximab-sensitive CRC cell lines. Caption Supplementary Figure 2. The BAY 86-9766 treatment, in CRC cancer cell lines with primary and acquired resistance to cetuximab, induce a dose dependent reduction of MAPK and MEK phosphorylation. Caption Supplementary Figure 3. The combined treatment of cetuximab and the selective MEK1/2 inhibitor BAY 86-9766 was well tolerated by mice, with no weight loss or other signs of acute or delayed toxicity. Caption Supplementary Table 1A and 1B. The panel of CRC cell lines have been treated with several concentrations of cetuximab and selective MEK1/2 inhibitors (BAY 86-9766, Selumetinib and Pimasertib), showing differential sensitivity to the drugs. Caption Supplementary Table 2. We have performed the experiments on a panel of eight human CRC cell lines having different mutation profiles in KRAS, NRAS, BRAF, PIK3CA and EGFR genes. Caption Supplementary Table 3. In the CRC cell lines with acquired and primary resistance to cetuximab, the treatment with the selective MEK1/2 inhibitor BAY 86-9766 determined synergistic growth inhibitory effects in combination with cetuximab.
Supplementary Figure Legends from Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition
Authors: Troiani Teresa , Napolitano Stefania , Vitagliano Donata , Morgillo Floriana , Capasso Anna , Sforza Vincenzo , Nappi Anna , Ciardiello Davide , Ciardiello Fortunato , Martinelli Erika
Published: April 2023

PDF file - 116KB